title: Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu.
abstract: In order to use adenovirus (Ad) type 5 (Ad5) for cancer gene therapy, Ad needs to be de-targeted from its native receptors and re-targeted to a tumor antigen. A limiting factor for this has been to find a ligand that (i) binds a relevant target, (ii) is able to fold correctly in the reducing environment of the cytoplasm and (iii) when incorporated at an optimal position on the virion results in a virus with a low physical particle to plaque-forming units ratio to diminish the viral load to be administered to a future patient. Here, we present a solution to these problems by producing a genetically re-targeted Ad with a tandem repeat of the HER2/neu reactive Affibody molecule (ZH) in the HI-loop of a Coxsackie B virus and Ad receptor (CAR) binding ablated fiber genetically modified to contain sequences for flexible linkers between the ZH and the knob sequences. ZH is an Affibody molecule specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) that is overexpressed in inter alia breast and ovarian carcinomas. The virus presented here exhibits near wild-type growth characteristics, infects cells via HER2/neu instead of CAR and represents an important step toward the development of genetically re-targeted adenoviruses with clinical relevance.
authors.affiliation: Got-a-Gene AB, Kullavik, Sweden.
authors.forename: M K
authors.initials: MK
authors.lastname: Magnusson
authors.forename: P
authors.initials: P
authors.lastname: Henning
authors.forename: S
authors.initials: S
authors.lastname: Myhre
authors.forename: M
authors.initials: M
authors.lastname: Wikman
authors.forename: T G
authors.initials: TG
authors.lastname: Uil
authors.forename: M
authors.initials: M
authors.lastname: Friedman
authors.forename: K M E
authors.initials: KM
authors.lastname: Andersson
authors.forename: S S
authors.initials: SS
authors.lastname: Hong
authors.forename: R C
authors.initials: RC
authors.lastname: Hoeben
authors.forename: N A
authors.initials: NA
authors.lastname: Habib
authors.forename: S
authors.initials: S
authors.lastname: Ståhl
authors.forename: P
authors.initials: P
authors.lastname: Boulanger
authors.forename: L
authors.initials: L
authors.lastname: Lindholm
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D001943:Breast Neoplasms / Q000628:therapy; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D008024:Ligands; D010051:Ovarian Neoplasms / Q000628:therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D008024:Ligands; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; C515865:Z(HER2.4)2 affibody